Sponsors (3)
The bill reduces consumer-facing pharmaceutical promotion—potentially lowering demand for expensive branded drugs and raising federal revenue—while risking higher out-of-pocket drug costs, reduced public awareness of therapies, and business and compliance burdens for advertisers and manufacturers.
Patients with chronic conditions may face less promotion-driven pressure to use higher-cost branded medicines, reducing demand for expensive prescriptions.
Taxpayers could see increased federal revenue because firms would lose a business tax deduction for direct-to-consumer (DTC) pharmaceutical advertising.
Hospitals, health systems, and clinicians may get better-targeted information if manufacturers shift marketing dollars from public ads to professional or peer-reviewed channels, improving clinician-focused information flow.
Patients (especially those with chronic conditions) and taxpayers could face higher drug prices if manufacturers pass higher after-tax advertising costs onto consumers.
Limiting public-facing advertising could reduce public awareness of newly available or clinically relevant therapies, potentially delaying patient access and informed treatment discussions.
Advertisers, marketing firms, digital platforms, and broadcasters that rely on pharmaceutical DTC campaigns could lose business and revenue, hurting small businesses and related jobs.
Based on analysis of 2 sections of legislative text.
Eliminates federal tax deductions for direct-to-consumer advertising expenses for covered prescription and compounded drugs.
Official title: Amend the Internal Revenue Code of 1986 to deny the deduction for advertising and promotional expenses for certain drugs.
Introduced May 15, 2025 by Joshua David Hawley · Last progress May 15, 2025
Disallows federal tax deductions for expenses related to direct-to-consumer (DTC) advertising for certain prescription drugs and compounded drug products. The rule applies to sponsors of prescription drug products and owners of outsourcing facilities and takes effect for amounts paid or incurred after enactment in taxable years ending after enactment.